Nuestros investigadores

María Inmaculada Colina Lorda

Publicaciones científicas más recientes (desde 2010)

Autores: Bastarrika, Gorka; Zulueta, Javier J; et al.
ISSN 1465-993X  Vol. 18  Nº 1  2017  págs. 175
Background: Chronic Obstructive Pulmonary Disease (COPD) is an independent risk factor for cardiovascular (CV) disease, one of the most frequent causes of death in COPD patients. The goal of the present study was to evaluate the prognostic value of non-invasive CV risk markers in COPD patients. Methods: CV risk was prospectively evaluated in 287 COPD patients using non-invasive markers including the Framingham score, the Systematic Coronary Risk Evaluation (SCORE) charts, coronary arterial calcium (CAC), epicardial adipose tissue (EAT), as well as clinical, biochemical and physiological variables. The predictive power of each parameter was explored using CV events as the main outcome. Results: During a median follow up of 65 months (ICR: 36-100), 44 CV events were recorded, 12 acute myocardial infarctions (27.3%), 10 ischemic heart disease/angina (22.7%), 12 peripheral artery disease events requiring surgery (27.3%) and 10 strokes (22.7%). A total of 35 CV deaths occurred during that period. Univariable analysis determined that age, hypertension, CRP, total Cholesterol, LDL-Cholesterol, Framingham score and CAC were independently associated with CV events. Multivariable analysis identified CAC as the best predictor of CV events (HR; 95%CI: 1.32; 1.19-1.46, p < 001). Conclusions: In COPD patients attending pulmonary clinics, CAC was the best independent non-invasive predictor of CV events. This tool may help evaluate the risk for a CV event in patients with COPD. Larger studies should reproduce and validate these findings.
Autores: González, A; Pueyo, Jesús Ciro; et al.
ISSN 1388-9842  Vol. 19  Nº Supl. 1  2017  págs. 123
Autores: González, Jéssica; Restituto, Patricia; et al.
ISSN 1073-449X  Vol. 193  2016  págs. A3554
Autores: Restituto, Patricia; et al.
ISSN 0009-9120  Vol. 47  Nº 18  2014  págs. 272-8
This study shows that OPG may potentially be a biomarker for cardiovascular risk/damage in the MS and identifies adipose tissue as a potential source of OPG.
Autores: Zulueta, Javier J; Bastarrika, Gorka; et al.
Revista: PLOS ONE
ISSN 1932-6203  Vol. 8  Nº 6  2013  págs. e65593
Autores: Restituto, Patricia; Monreal, José Ignacio; et al.
ISSN 0021-972X  Vol. 98  Nº 11  2013  págs. E1740 - E1748
Context: Bone turnover markers (BTMs) may identify changes in bone remodeling within a relatively short time interval before changes in bone mineral density can be detected. New markers such as osteoprotegerin, receptor activator of nuclear factor-B ligand, and sclerostin have emerged, but there is little information about their potential use in clinical practice. Design, Patients, and Setting: We performed an observational prospective study in pre-and postmenopausal ambulatory women (n =72 and n =152, respectively). Intervention: Postmenopausal women with osteoporosis (n =18) were treated with risedronate and calcium. Womenfilled out a questionnaire and underwent bone mineral density measurement using dual-energy x-ray absorptiometry at the time of enrollment and after 1 year of follow-up. BTMs were measured at baseline, at 6 months, and after 1 year. Results: Increased levels of N-terminal propeptide of type 1 procollagen (P1NP) and beta-type I collagen telopeptides (CTXs) were associated with low bone mineral density in the premenopausal (P =.02 and P =.04, respectively) and postmenopausal (P =.03 and P =.02) groups. The best analytical performance to diagnose osteoporosis was for = -CTX, osteocalcin, and P1NP, with areas under the curve of 0.70 (P =.005), 0.64 (P =.048), and 0.71 (P =.003). A significant decrease was found in P1NP, osteocalcin, tartrate-resistant acid phosphatase-5b, =-CTX, and bone alkaline phosphatase after 1 year of treatment (all P =.05). Conclusions: Our data suggest that measurement of beta beta-CTX and P1NP shows adequate analytical performance and could potentially be included in algorithms for the screening of osteoporosis. Furthermore, these two markers, along with osteocalcin and tartrate-resistant acid phosphatase5b, are useful to monitor the response to risedronate.
Autores: Rodríguez, Amaia; Gómez-Ambrosi, J; Catalán, V; et al.
Revista: Diabetologia
ISSN 0012-186X  Vol. 55  Nº 11  2012  págs. 3038 - 3050
Autores: Landecho, Manuel Fortún; Colina, María Inmaculada; Huerta, Ana; et al.
ISSN 0300-8932  Vol. 64  Nº 5  2011  págs. 373-378
Insulin resistance and all metabolic syndrome traits except low level of high-density lipoproteins were significantly associated with an increased OR for EKD. Both metabolic syndrome and EKD were independently and additively related to the presence of surrogate markers of arteriosclerosis
Autores: Rodríguez, Amaia; Gómez-Ambrosi, J; Catalán, V; et al.
Revista: Journal of hypertension
ISSN 0263-6352  Vol. 28  Nº 3  2010  págs. 560 - 567
Objective The gut-derived hormone, ghrelin, improves cardiac function in healthy individuals and patients with chronic heart failure. The aim of this study was to investigate whether the major isoforms of the hormone, acylated and desacyl ghrelin, are related to inappropriate left ventricular mass in patients with the metabolic syndrome (MetS). Methods and results Plasma concentrations of ghrelin forms were measured in 180 white participants (65 normal weight, 60 obese without MetS and 55 obese with MetS; 56% men). MetS was defined according to Adult Treatment Panel III criteria. The presence of left ventricular hypertrophy (LVH) was diagnosed by sex-specific left ventricular mass/height(2.7) cut-off values (> 49.2 g/m(2.7) for men and > 46.7 g/m(2.7) for women). Circulating concentrations of acylated ghrelin were increased in obesity and MetS, whereas desacyl ghrelin levels were decreased. Compared with participants in the lowest tertiles, the age-adjusted and sex-adjusted odds of having MetS were lower in the highest category of desacyl ghrelin (odds ratio 0.1, 95% confidence interval 0.1-0.4, P < 0.001). The prevalence of LVH was increased in the highest tertile of acylated ghrelin (odds ratio 3.4, 95% confidence interval 1.7-5.6, P < 0.05). Plasma acylated ghrelin was increased (P < 0.05) in patients with MetS exhibiting LVH compared with those with appropriate left ventricular mass, whereas plasma desacyl ghrelin was not changed (P = 0.490). Conclusion Acylated ghrelin was positively associated with SBP and left ventricular mass indices, even after correction for BMI. These results suggest that the increased acylated ghrelin concentrations may represent a compensatory mechanism to overcome the development of hypertension and LVH in patients with MetS.
Autores: Restituto, Patricia; Colina, María Inmaculada; Varo, José Javier; et al.
Revista: American journal of physiology: endocrinology and metabolism
ISSN 0193-1849  Vol. 298  Nº 5  2010  págs. 1072 - 1077
Autores: Lucena, Juan Felipe; Quiroga, Jorge Augusto; Colina, María Inmaculada; et al.
Título: Orina
Libro:  La clínica y el laboratorio.
2015  págs. 159-194
Autores: Lucena, Juan Felipe; Quiroga, Jorge Augusto; Colina, María Inmaculada; et al.
Título: Orina
Libro:  Balcells. La clínica y el laboratorio
2015  págs. 159-193
Autores: Lavilla, Francisco Javier; Lucena, Juan Felipe; Bustos, M; et al.
Libro:   La clínica y el laboratorio.
2015  págs. 587-616
Autores: D'Avola, Delia; Colina, María Inmaculada; Quiroga, Jorge Augusto;
Libro:  Hepatología. De las ciencias básicas a las clínicas. De los problemas a los síndromes. De la docencia a la práctica médica
2015  págs. 155 - 168
Autores: Lavilla, Francisco Javier; Lucena, Juan Felipe; Colina, María Inmaculada;
Libro:  Balcells. La clínica y el laboratorio
Nº 22ª Edición  2015  págs. 587-616
Autores: Pascual, Juan Ignacio; Colina, María Inmaculada; et al.
Libro:  Balcells. La clínica y el laboratorio
2015  págs. 617-28
Autores: Lavilla, Francisco Javier; Lucena, Juan Felipe; Colina, María Inmaculada;
Libro:  La Clínica y el Laboratorio: interpretación de análisis y pruebas funcionales. Exploración de los síndromes. Cuadro biológico de las enfermedades
2010  págs. 509-532
Autores: Pascual, Juan Ignacio; Colina, María Inmaculada; Rincón, Aníbal ; et al.
Libro:  La clínica y el laboratorio
2010  págs. 533 - 542
Autores: Lucena, Juan Felipe; Quiroga, Jorge Augusto; Colina, María Inmaculada; et al.
Título: Orina
Libro:  La clínica y el laboratorio
2010  págs. 149 - 181